Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

The Zepbound LillyDirect offers comes in a single-dose vial rather than as an auto-injector pen, also called a Zepbound ... Generally, Zepbound starter doses will be the lowest dose available.

The singer shared that she was dropped by her record label for "being too fat" and confessed, "I thought I needed Ozempic to be beautiful and successful." Recent tests revealed she has ...

To use Ozempic, you must consult an endocrinologist or a healthcare professional specialising in diabetes management. The medication is administered via a pre-filled injection pen, usually once a ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient, they are approved for different purposes. Ozempic is ...

Ozempic is self-administered with an injection pen Credit: Carolina Rudah “People are living another 10 to 15 years and they want to look what they feel like, not what they may physically look ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. With approximately 70% of American adults meeting the criteria for being obese or ...

Ozempic becomes the first GLP-1 treatment option for people with type 2 diabetes and chronic kidney disease Mario Tama/Getty The Food and Drug Administration has approved Ozempic to reduce the ...

Amy Schumer once hopped on board the Ozempic trend, but the side effects were so intense she had to stop. During a recent appearance on "The Howard Stern Show," the comedian, 43, opened up about ...

GLP-1 receptor agonist medications like Ozempic may do more than just change your waistline—they could influence how you shop at the grocery store. That’s the major takeaway from a new study ...